Logo

Roche Acquires Inflazome for ~$450M

Share this

M&A

Roche Acquires Inflazome for ~$450M

Shots:

  • Inflazome to receive $450.31M as up front and is eligible to receive additional contingent payments based on the achievement of certain predetermined milestones
  • The acquisition allows the Roche to get full rights to Inflazome’s portfolio consisting of pre/ clinical orally available small molecule NLRP3 inhibitors
  • Roche will further advance the NLRP3 inhibitors across a wide variety of indications targeting the unmet medical needs across a wide variety of inflammatory diseases

­ Ref: PRNewswire | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions